Gustavo Maegawa | Biochemistry | Innovative Research Award

Published on by Research Awards

Innovative Research Award

Gustavo Maegawa — Columbia University Irving Medical Center, United States

Gustavo Maegawa
Affiliation Columbia University Irving Medical Center
Country United States
Scopus ID 14522943200
Documents 54
Citations 2,549
h-index 25
Subject Area Biochemistry
Event International Research Awards
ORCID 0000-0001-6933-4138

Gustavo Maegawa is a physician-scientist and academic researcher affiliated with Columbia University Irving Medical Center. His documented academic work includes clinical genetics, genomics, lysosomal storage disorders, and biochemical research, with publications addressing inherited metabolic diseases and related molecular mechanisms. Bibliographic records supplied for this recognition profile report 54 documents, 2,549 citations, and an h-index of 25.[1]

Abstract

Gustavo Maegawa is a physician-scientist affiliated with Columbia University Irving Medical Center whose research spans clinical genetics, genomics, biochemical investigation, and lysosomal storage disorders. His academic record includes research addressing inherited metabolic diseases and molecular mechanisms relevant to rare disorders. Publicly indexed publications identify his participation in multidisciplinary studies involving disease mechanisms, screening, therapeutic development, and molecular characterization.[1][2] Bibliographic information supplied for this profile records 54 documents, 2,549 citations, and an h-index of 25. His research activity therefore provides a basis for recognition under an Innovative Research Award framework, particularly through sustained scholarly contribution and interdisciplinary biomedical investigation. Recent publications further demonstrate continued involvement in research on lysosomal and inherited metabolic disorders.[1]

Keywords

Gustavo Maegawa; Innovative Research Award; Columbia University Irving Medical Center; biochemistry; clinical genetics; genomics; lysosomal storage disorders; inherited metabolic diseases; rare diseases; biomedical research; translational research; molecular medicine.[1]

Introduction

Gustavo Maegawa is identified by Columbia University as an Associate Professor of Pediatrics with academic expertise in clinical genetics and genomics. His research has focused particularly on lysosomal storage disorders, a group of inherited metabolic conditions involving defects in cellular degradation pathways.[1]

Research Profile

The research profile associated with Gustavo Maegawa encompasses clinical genetics, genomics, biochemical research, and lysosomal storage disorders. Columbia University describes his research focus as including lysosomal storage disorders and his professional expertise as clinical genetics and genomics.[1]

Research Contributions

His publication record also includes research related to newborn screening for lysosomal storage disorders. A 2024 study examining screening for six lysosomal storage disorders in China included Maegawa as a co-author and identified Columbia University affiliations.[5]

Publications

Selected publications involving Gustavo Maegawa demonstrate a research emphasis on rare diseases, inherited metabolic disorders, molecular mechanisms, and translational biomedical investigation. The following examples are drawn from indexed bibliographic records and are presented as representative publications rather than as a complete bibliography.[1]

Research Impact

Beyond citation indicators, the subject areas represented in the publication record are relevant to clinical genetics and rare-disease research. Studies involving lysosomal storage disorders, genetic screening, molecular mechanisms, and potential therapeutic strategies demonstrate connections between laboratory investigation and clinically relevant questions.[3][5]

Award Suitability

The Innovative Research Award is aligned with a research profile demonstrating sustained scholarly activity and contributions to scientific investigation. Gustavo Maegawa’s documented work in clinical genetics, genomics, biochemical research, and lysosomal storage disorders provides a relevant academic basis for consideration under this recognition category.[1]

Conclusion

Gustavo Maegawa’s research profile reflects sustained involvement in clinical genetics, genomics, biochemistry, and lysosomal storage disorder research. His publications address clinically and biologically significant questions involving inherited metabolic diseases, screening, molecular mechanisms, and therapeutic investigation.[3][4]

References

  1. Begum, S., Hsueh, S.-C., Cheria, E. M. Y., et al. Sphingolipid-neutralizing molecular therapy reduces psychosine cytotoxicity in Krabbe disease. iScience, 29(3), 114808, 2026. DOI: https://doi.org/10.1016/j.isci.2026.114808
  2. Yi, M., Wang, Y., Gao, X., et al. Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA. Journal of Inherited Metabolic Disease, 45(3), 593–604, 2022.
    https://doi.org/10.1002/jimd.12491
  3. Maegawa, G. H. B., Tropak, M. B., Buttner, J. D., Rigat, B. A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G. J., Hamuro, Y., Clarke, J. T. R., & Mahuran, D. J. (2009). Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. Journal of Biological Chemistry, 284(35), 23502–23516.
    https://doi.org/10.1074/jbc.M109.012393

  4. Santelices, J., Ou, M., Maegawa, G. H. B., et al. USP8 inhibition regulates autophagy flux and controls Salmonella infection. Frontiers in Cellular and Infection Microbiology, 13, 1070271, 2023.  https://doi.org/10.3389/fcimb.2023.1070271
  5. Mallack, E. J., Turk, B. R., Yan, H., Price, C., Demetres, M., Moser, A. B., Becker, C., Hollandsworth, K., Adang, L., Vanderver, A., & Van Haren, K. (2021). MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. Journal of Inherited Metabolic Disease.
    https://doi.org/10.1002/jimd.12356 

Zu-Chian Chiang | Biochemistry | Best Researcher Award | 13347

Published on by Research Awards

Dr. Zu-Chian Chiang | Biochemistry | Best Researcher Award 

Dr. Zu-Chian Chiang, Fujian Normal University, China

Dr. Zu-Chian Chiang is a postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, China, with a rich background in materials and chemical engineering. His research contributions span antibody-drug conjugates (ADCs), functional peptide synthesis, biomaterials for regenerative medicine, and aptamer-based cancer therapy. His work has geographic impact across Taiwan and Mainland China, contributing to translational medicine and oncology through collaborative efforts with prestigious institutions like Academia Sinica and National Taiwan University. His applied research in ADCs and biomaterial scaffolds directly supports cancer treatment innovations. Notable projects include the development of CD47-targeting ADCs for non-small cell lung cancer, and thalidomide-PD1 combinations for enhanced immunotherapy. His publications in Frontiers in Oncology, PLOS ONE, and Current Pharmaceutical Biotechnology highlight his influence in drug delivery and cancer therapeutics. In the vector control domain, his scaffold research contributes to potential localized drug delivery systems. Dr. Chiang has received awards such as the Science and Technology Commissioner honor from Quanzhou and the Biotech Elite Training Award. His achievements exemplify impactful biomedical research with real-world therapeutic implications.

Profile

Scopus

🌱 Early Academic Pursuits

Dr. Zu-Chian Chiang embarked on his scientific journey with a passion for chemistry and materials science. He earned his Master’s Degree in Chemistry from Tunghai University, Taiwan (2005–2007), under the guidance of Prof. Feng-Di Lung. Building on this solid foundation, he pursued his Ph.D. in Materials and Chemical Engineering at National United University, Taiwan (2008–2014). During his doctoral studies, he was mentored by Prof. An-Chong Chao and co-advised by Dr. Guo-Chung Dong, focusing on biomaterials and nanomedicine.

Even as a student, Dr. Chiang demonstrated exceptional academic capabilities, earning scholarships and recognition for his innovative research. His academic training laid the groundwork for his future contributions in biomedical engineering and cancer therapeutics.

🧪 Professional Endeavors

Dr. Chiang has held several prestigious postdoctoral positions. His professional journey reflects a commitment to interdisciplinary collaboration and translational research:

  • Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University (2019–Present), working under Prof. Qi Chen.

  • Postdoctoral Fellow at the Institute of Biological Chemistry, Academia Sinica, Taiwan (2016–2019), contributing to the Taiwan Protein Project (TPP) and the Technical Support Platform Spindle Project (TSPA).

  • Postdoctoral Fellow at the Clinical Trial Center, National Taiwan University Hospital (2015–2016), supported by Taiwan’s prestigious Biotech Elite Training Program.

Throughout these roles, Dr. Chiang has engaged in cutting-edge biomedical research with direct implications for drug development and clinical applications.

🔬 Contributions and Research Focus

Dr. Chiang’s research centers on innovative therapeutic materials and drug delivery systems, particularly in cancer therapy. His core interests include:

  • Antibody-Drug Conjugates (ADCs): Targeted cancer therapies such as HER2-positive and CD47-specific ADCs.

  • Functional Peptide Synthesis for bone tissue engineering and cancer inhibition.

  • Bio-Micro-Macro Molecular Materials for regenerative medicine.

  • Aptamer Development as modulators in therapeutic settings.

Notable publications include research on CD47-targeting ADCs (Frontiers in Oncology, 2022) and HER2-positive ADCs (PLOS ONE, 2020). His work on dexamethasone-immobilized chitosan scaffolds and chitosan-caffeic acid hybrids also provides valuable insights into localized drug delivery and tissue engineering.

🏆 Accolades and Recognition

Dr. Chiang’s dedication has been acknowledged through numerous awards:

  • 🥇 Science and Technology Commissioner, Quanzhou, Fujian Province (2020)

  • 🥇 Biotech Elite Training Award, National Taiwan University & Ministry of Science and Technology (2016)

  • 🥇 Chung Hwa Rotary Doctoral Program Award, Taiwan (2012)

  • 🥇 Outstanding Doctoral Scholarship, National United University (2010)

  • 🥇 Master’s Program Scholarship, Hunan Fellow Association of Taiwan (2007)

  • 🥇 Rotary Leadership Award, Miaoli Southeastern Xindong Satellite Rotary Club (2017)

These accolades affirm his position as a respected figure in the fields of biomedical chemistry and translational medicine.

🌍 Impact and Influence

Dr. Chiang’s work has made a geographic impact spanning Taiwan and Mainland China. His collaborative research in academia and clinical centers bridges the gap between laboratory research and therapeutic application. He actively contributes as a peer reviewer for the International Journal of Biological Macromolecules, influencing scientific standards and publication quality globally.

He is also engaged in community service through leadership in Rotary International, fostering science-driven community development and education.

🌟 Legacy and Future Contributions

Dr. Chiang’s legacy is being built on the foundation of scientific excellence, mentorship, and translational impact. His research not only pushes the boundaries of biomedical engineering but also aims to enhance the effectiveness of cancer treatments in clinical practice. With a commitment to developing next-generation targeted therapies and biomaterial scaffolds, Dr. Chiang is poised to shape the future of personalized medicine and regenerative technologies.

Looking ahead, he aims to establish interdisciplinary collaborations and contribute to global health initiatives, making life-saving therapies more effective and accessible.

Publication Top Notes

Development of Novel CD47-Specifific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. 

Author: Z.C., Chiang, Zu Chian, S., Fang, Shubin, Y., Shen, Yangkun, … J., Lin, Jizhen, Q., Chen, Qi

Journal: Frontiers in Oncology,

Year: 2022

Preparation and characterization of dexamethasone-immobilized chitosan scaffold

Author: Z.C., Chiang, Zu Chian, S., Yu, Shuhuei, A., Chao, Anchong, G.C., Dong, Guo Chung

Journal: Journal of Bioscience and Bioengineering, 

Year: 2012